Free shipping on all orders over $ 500

Etomoxir

Cat. No. M9048

All AbMole products are for research use only, cannot be used for human consumption.

Etomoxir Structure
Synonym:

(R)-(+)-Etomoxir

Size Price Availability Quantity
1mg USD 35 In stock
5mg USD 75 In stock
10mg USD 138 In stock
25mg USD 245 In stock
50mg USD 360 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1). Etomoxir binds irreversibly to the catalytic site of CPT-1 inhibiting its activity, but also upregulates fatty acid oxidation enzymes.

In vivo, Rats treated with Etomoxir (injected daily for 8 days at 20 mg/kg of body mass) display a 44% reduced cardiac CPT-I activity. The treatment of Lewis rats for 8 days with 20 mg/kg Etomoxir does not alter blood glucose, which is in line with comparable etomoxir-feeding studies.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines SF188 glioblastoma cells
Preparation method Cells were harvested and suspended at 1 × 10^6 cells/ml in phosphate buffered saline (PBS) supplementedwith 25 mM glutamine and 6 mM L-glutamine. They were and treated with 1 mM etomoxir for 25 minutes.
Concentrations 1 mM
Incubation time 25 minutes
Animal Experiment
Animal models Male BALB/c nude mice
Formulation Not mentioned
Dosages 40 mg/kg
Administration Intraperitoneal injection
Chemical Information
Molecular Weight 326.82
Formula C17H23ClO4
CAS Number 124083-20-1
Solubility (25°C) DMSO: ≥ 40 mg/mL
Storage -20°C, protect from light, sealed
References

[1] Li J, et al. Sci Rep. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus.

[2] Luiken JJ, et al. Biochem J. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.

Related PPAR Products
WY 14643 (Pirinixic Acid)

WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist.

Rosiglitazone

Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor.

GSK 3787

GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6).

Rosiglitazone maleate

Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM.

Ciprofibrate

Ciprofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Etomoxir, (R)-(+)-Etomoxir supplier, PPAR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.